Zacks Investment Research upgraded shares of ITUS (NYSE:ANIX) from a sell rating to a hold rating in a research report sent to investors on Wednesday.
According to Zacks, “Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States. “
Shares of ANIX stock opened at $5.10 on Wednesday. ITUS has a 52-week low of $2.96 and a 52-week high of $6.86.
ITUS Company Profile
Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.
Further Reading: How accurate is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.